201 related articles for article (PubMed ID: 28524155)
1. Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study.
Gray RT; Loughrey MB; Bankhead P; Cardwell CR; McQuaid S; O'Neill RF; Arthur K; Bingham V; McGready C; Gavin AT; James JA; Hamilton PW; Salto-Tellez M; Murray LJ; Coleman HG
Br J Cancer; 2017 Jun; 116(12):1652-1659. PubMed ID: 28524155
[TBL] [Abstract][Full Text] [Related]
2. Statin Use After Diagnosis of Colon Cancer and Patient Survival.
Voorneveld PW; Reimers MS; Bastiaannet E; Jacobs RJ; van Eijk R; Zanders MMJ; Herings RMC; van Herk-Sukel MPP; Kodach LL; van Wezel T; Kuppen PJK; Morreau H; van de Velde CJH; Hardwick JCH; Liefers GJ
Gastroenterology; 2017 Aug; 153(2):470-479.e4. PubMed ID: 28512021
[TBL] [Abstract][Full Text] [Related]
3. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.
Ng K; Ogino S; Meyerhardt JA; Chan JA; Chan AT; Niedzwiecki D; Hollis D; Saltz LB; Mayer RJ; Benson AB; Schaefer PL; Whittom R; Hantel A; Goldberg RM; Bertagnolli MM; Venook AP; Fuchs CS
J Natl Cancer Inst; 2011 Oct; 103(20):1540-51. PubMed ID: 21849660
[TBL] [Abstract][Full Text] [Related]
4. HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome.
Bengtsson E; Nerjovaj P; Wangefjord S; Nodin B; Eberhard J; Uhlén M; Borgquist S; Jirström K
Diagn Pathol; 2014 Apr; 9():78. PubMed ID: 24708688
[TBL] [Abstract][Full Text] [Related]
5. Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study.
Krens LL; Simkens LH; Baas JM; Koomen ER; Gelderblom H; Punt CJ; Guchelaar HJ
PLoS One; 2014; 9(11):e112201. PubMed ID: 25375154
[TBL] [Abstract][Full Text] [Related]
6. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
[TBL] [Abstract][Full Text] [Related]
7. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
8. The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.
Butt S; Butt T; Jirström K; Hartman L; Amini RM; Zhou W; Wärnberg F; Borgquist S
Ann Surg Oncol; 2014 Sep; 21(9):2911-9. PubMed ID: 24777857
[TBL] [Abstract][Full Text] [Related]
9. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
10. A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes.
Liu G; Shi M; Mosley JD; Weng C; Zhang Y; Lee MTM; Jarvik GP; Hakonarson H; Namjou-Khales B; Sleiman P; Luo Y; Mentch F; Denny JC; Linton MF; Wei WQ; Stein CM; Feng Q
JAMA Netw Open; 2021 Jun; 4(6):e2112820. PubMed ID: 34097045
[TBL] [Abstract][Full Text] [Related]
11. Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase.
Göbel A; Pählig S; Motz A; Breining D; Traikov S; Hofbauer LC; Rachner TD
Biochem Biophys Res Commun; 2024 May; 710():149841. PubMed ID: 38588613
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
[TBL] [Abstract][Full Text] [Related]
13. Statin use after colorectal cancer diagnosis and survival: a population-based cohort study.
Cardwell CR; Hicks BM; Hughes C; Murray LJ
J Clin Oncol; 2014 Oct; 32(28):3177-83. PubMed ID: 25092779
[TBL] [Abstract][Full Text] [Related]
14. The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer.
McCuaig S; Barras D; Mann EH; Friedrich M; Bullers SJ; Janney A; Garner LC; Domingo E; Koelzer VH; Delorenzi M; Tejpar S; Maughan TS; West NR; Powrie F
Clin Cancer Res; 2020 Aug; 26(16):4313-4325. PubMed ID: 32430479
[TBL] [Abstract][Full Text] [Related]
15. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.
Bhardwaj A; Singh H; Trinidad CM; Albarracin CT; Hunt KK; Bedrosian I
Breast Cancer Res; 2018 Dec; 20(1):150. PubMed ID: 30537987
[TBL] [Abstract][Full Text] [Related]
16. Statin use, HMGCR expression, and breast cancer survival - The Malmö Diet and Cancer Study.
Bjarnadottir O; Feldt M; Inasu M; Bendahl PO; Elebro K; Kimbung S; Borgquist S
Sci Rep; 2020 Jan; 10(1):558. PubMed ID: 31953433
[TBL] [Abstract][Full Text] [Related]
17. Statin use and survival in colorectal cancer: Results from a population-based cohort study and an updated systematic review and meta-analysis.
Gray RT; Coleman HG; Hughes C; Murray LJ; Cardwell CR
Cancer Epidemiol; 2016 Dec; 45():71-81. PubMed ID: 27750068
[TBL] [Abstract][Full Text] [Related]
18. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
Göbel A; Breining D; Rauner M; Hofbauer LC; Rachner TD
Cell Death Dis; 2019 Jan; 10(2):91. PubMed ID: 30692522
[TBL] [Abstract][Full Text] [Related]
19.
Charlton ME; Kahl AR; Greenbaum AA; Karlitz JJ; Lin C; Lynch CF; Chen VW
J Natl Compr Canc Netw; 2017 Dec; 15(12):1484-1493. PubMed ID: 29223986
[No Abstract] [Full Text] [Related]
20. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
Bjarnadottir O; Romero Q; Bendahl PO; Jirström K; Rydén L; Loman N; Uhlén M; Johannesson H; Rose C; Grabau D; Borgquist S
Breast Cancer Res Treat; 2013 Apr; 138(2):499-508. PubMed ID: 23471651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
